Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open. 2013; 3(9):e003250 334. Tilson L, McGowan B, Ryan M, Barry M. Cost-effectiveness of spironolactone in patients with severe heart failure. Irish Journal of Medical Science. 2003; 172(2):70-72 335. Toblli JE, Di Gennaro F, Rivas C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart, Lung & Circulation. 2015; 24(7):686-95 336. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. Journal of the American College of Cardiology. 2007; 50(17):1657-65 337. Townsend N, Bhatnagar P, Wilkins E. Cardiovascular disease statistics. London. 2015. Available from: https://www.bhf.org.uk/publications/statistics/cvd-stats-2015 338. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 mortality and hospitalization: an individual patient meta-analysis. European Heart Journal. 339. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) 340. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT- proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. European Heart Journal. 2005; 26(21):2277- 341. Tsuchihashi-Makaya M, Matsuo H, Kakinoki S, Takechi S, Kinugawa S, Tsutsui H et al. Home- based disease management program to improve psychological status in patients with heart failure in Japan. Circulation Journal. 2013; 77(4):926-33 342. 